JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben reiterates a Market Outperform rating on Crinetics Pharmaceuticals (CRNX) and maintains an $80 price target.
May 10, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirmed a Market Outperform rating on Crinetics Pharmaceuticals with an $80 price target, indicating a positive outlook on the stock.
The reiteration of a Market Outperform rating and maintenance of an $80 price target by JMP Securities suggests a strong confidence in Crinetics Pharmaceuticals' future performance. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100